Arrowhead Research (ARWR) Reports Closing of License and Collaboration Agreement with Amgen (AMGN) on RNAi ARC-LPA Program

November 21, 2016 11:34 AM EST

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is pleased to announce that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA program has closed, following early termination of the waiting period under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended.


ARC-LPA is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. ARC-LPA is Arrowhead’s first drug candidate to use a subcutaneously administered delivery construct.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News

Related Entities


Add Your Comment